Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soriot Stands By His Post-Pfizer Sales Pledge For AstraZeneca

Executive Summary

Pascal Soriot stands by the ambitious growth target he set for AstraZeneca in his defense against Pfizer's 2014 bid for the company. Any shortfall in the target of $45bn by 2023 will reflect the weakening of the dollar rather than product challenges for the UK company, the bullish CEO told Scrip one day after the company delivered disappointing Phase III data that slashed around 15% from its share price.

Advertisement

Related Content

Pharma Q3 Results Preview: Pfizer, Allergan, Sanofi, Teva & AstraZeneca
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel